相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK
Rossana Maffei et al.
LEUKEMIA (2021)
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
Kai Tang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
Adaobi Amobi-McCloud et al.
FRONTIERS IN IMMUNOLOGY (2021)
IDO1-Targeted Therapy Does Not Control Disease Development in the Eμ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
Selcen Ozturk et al.
CANCERS (2021)
The Tumor Microenvironment-Dependent Transcription Factors AHR and HIF-1α Are Dispensable for Leukemogenesis in the Eμ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
Susanne Gonder et al.
CANCERS (2021)
AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia
Xue Yi et al.
CLINICAL CANCER RESEARCH (2020)
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
Arnon P. Kater et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?
Marco V. Haselager et al.
FRONTIERS IN ONCOLOGY (2020)
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
Michael Hallek
AMERICAN JOURNAL OF HEMATOLOGY (2019)
The Plasma [Kynurenine]/[Tryptophan] Ratio and Indoleamine 2,3-Dioxygenase: Time for Appraisal
Abdulla A-B Badawy et al.
INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH (2019)
Regulation of the Immune Response by the Aryl Hydrocarbon Receptor
Cristina Gutierrez-Vazquez et al.
IMMUNITY (2018)
Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities
Jae Eun Cheong et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling
Mingxiang Ye et al.
CLINICAL CANCER RESEARCH (2018)
Development of venetoclax for therapy of lymphoid malignancies
Huayuan Zhu et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Rescue of IL-1β-induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants
Alessandra Borsini et al.
BRAIN BEHAVIOR AND IMMUNITY (2017)
BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199
Kamil Bojarczuk et al.
BLOOD (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD plus and inhibits in vivo tumor growth
Yanling Liu et al.
ONCOTARGET (2016)
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
G. S. Choudhary et al.
CELL DEATH & DISEASE (2015)
Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival
Debbie M. Ferns et al.
ONCOIMMUNOLOGY (2015)
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
Jacques C. Mbongue et al.
VACCINES (2015)
CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
Regina Jitschin et al.
BLOOD (2014)
Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages
Paolo Giannoni et al.
HAEMATOLOGICA (2014)
Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199
S. L. Khaw et al.
LEUKEMIA (2014)
Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression
Jing-Yi Chen et al.
BREAST CANCER RESEARCH (2014)
Tumor-induced host immunosuppression: Special focus on CLL
Christine E. Cutucache
INTERNATIONAL IMMUNOPHARMACOLOGY (2013)
IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
Derek A. Wainwright et al.
CLINICAL CANCER RESEARCH (2012)
Indoleamine 2,3-Dioxygenase Activity and Expression in Patients With Chronic Lymphocytic Leukemia
Vesa Lindstrom et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients
Reinhart Speeckaert et al.
EUROPEAN JOURNAL OF CANCER (2012)
Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma
Soranobu Ninomiya et al.
LEUKEMIA & LYMPHOMA (2012)
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Luc Pilotte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
Tomoko Inaba et al.
GYNECOLOGIC ONCOLOGY (2009)
Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-γ
Selim Corm et al.
LEUKEMIA RESEARCH (2009)
Aryl hydrocarbon receptor inhibition downregulates the TGF-β/Smad pathway in human glioblastoma cells
D. Gramatzki et al.
ONCOGENE (2009)
Reduction of B cell turnover in chronic lymphocytic leukaemia
Julien Defoiche et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells
A Petlickovski et al.
BLOOD (2005)
The mammalian basic helix-loop-helix/PAS family of transcriptional regulators
RJ Kewley et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Tryptophan and the immune response
JR Moffett et al.
IMMUNOLOGY AND CELL BIOLOGY (2003)
Tolerance, DCs and tryptophan: much ado about IDO
U Grohmann et al.
TRENDS IN IMMUNOLOGY (2003)
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase
G Frumento et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
分享论文
